


VACCINE EFFICACY TRIALS PIPELINE



RV144
31% efficacy
2003-2009
ALVAC/AIDSVAX
Clade B, A/E
Thailand

HVTN 097
Phase Ib
ALVAC/AIDSVAX
Clade B/E

HVTN 100
Phase I/II
ALVAC/gp120
Clade C

HVTN 702
Uhambo
Estimated completion: July 2021
Phase IIb/III
ALVAC/gp120
Clade C

Development Track
South Africa
Designed to lead to a product submitted for regulatory approval and eventual public health introduction.

HVTN 702
stopped early for non-efficacy

Pox-Protein
P5, GSK, Sanofi
Pasteur

Research Track
Southern Africa and US
Designed to identify components of an effective vaccine strategy.

Phase I and I/IIa prime-boost candidates with varying vectors, primes, boosts and adjuvants
Clade C

HVTN 107

HVTN 111

HVTN 108

HVTN 120

Ad26
Janssen

Phase I
MVA Mosaic boost
USA

HIV-V-A002/MENSCH

Phase I
gp140 + adjuvant
USA

HIV-V-A003

Phase I/II
Ad26.Mos.HIV + Ad26, MVA or gp140 boost
Rwanda, South Africa, Thailand, Uganda, USA

HIV-V-A004/APPROACH

Phase I and I/II Ad26 mosaic, Clade C or mosaic gp140
Kenya, Rwanda, USA

HPX2004/HVTN 117/TRAVERSE

HPX1002

HPX2003/HVTN 118/ASCENT

HPX2008/HVTN 705
Imbokodo
Estimated completion: 2022

Phase IIb
Ad26.Mos4.HIV + gp140
South Africa, Zambia, Zimbabwe, Malawi, Mozambique

HPX3002/HVTN 706
Mosaico
Estimated completion: 2023

Phase III
Ad26.Mos4.HIV + Clade C gp140 and Mosaic gp140
Argentina, Brazil, Italy, Mexico, Peru, Poland, Spain, United States

PrEPVacc
Imperial College, MRC/UVRI & LSHTM, EDCTP, UCL, IAVI, CHUV/EFV

PrEPVacc
Registration Cohort

PrEPVacc
EST. 2020-2023

Phase IIb
DNA+AIDSVAX Clade B/E or DNA+gp140 Clade C/MVA+gp140 Clade C with TAF/FTC or TDF/FTC
Mozambique, South Africa, Tanzania, Uganda

KEY: ○ Completed ● Ongoing ✖ Planned